Diabetic eye complications, particularly diabetic retinopathy, represent a leading cause of preventable blindness among working-age adults worldwide. The global prevalence of diabetes continues to rise, and with it the burden of vision-threatening retinopathy. According to the International Diabetes Federation, the number of adults living with diabetes is projected to reach 783 million by 2045, driving an even greater demand for effective and sustainable eye care interventions. The World Health Organization estimates that diabetic retinopathy accounts for approximately 2.6% of global blindness, a figure that is expected to climb as diabetes incidence increases in low- and middle-income countries. Managing these complications effectively is not only a clinical priority but also an economic imperative. Dual therapy—combining two treatment modalities such as anti‑VEGF injections with laser photocoagulation or corticosteroids—has emerged as a strategy to improve visual outcomes. However, healthcare systems must carefully evaluate the economic impact of adopting dual therapy to ensure that limited resources are used efficiently. This article examines the economic dimensions of dual therapy in diabetic eye care, explores the evidence for cost‑effectiveness, discusses the trade‑offs that policymakers and providers face, and offers concrete recommendations for maximizing value.

The Rising Global Burden of Diabetic Eye Disease

Prevalence and Projections

Diabetic retinopathy (DR) affects approximately one‑third of people with diabetes, and diabetic macular edema (DME)—the most common cause of vision loss in DR—can dramatically impair daily life. The economic consequences are substantial: direct medical costs for treating DR in the United States exceed $500 million annually, and indirect costs from lost productivity, caregiver burden, and disability further strain economies. Vision loss reduces employment rates, lowers income, and increases reliance on social support systems. As the diabetic population grows, the financial pressure on healthcare systems intensifies, making cost‑effective interventions more critical than ever. Globally, the economic burden is even larger. A 2023 study in Diabetes Care estimated that the total cost of DR worldwide could reach $30 billion annually by 2045 if current trends continue, with low-income countries bearing a disproportionate share due to limited access to screening and treatment.

Understanding Dual Therapy Mechanisms

Dual therapy in diabetic eye care typically pairs a pharmacologic agent with a physical or interventional modality. The most common combinations include:

  • Anti‑VEGF injections plus focal/grid laser: Anti‑vascular endothelial growth factor (e.g., ranibizumab, aflibercept, bevacizumab) reduces vascular leakage and neovascularization, while laser photocoagulation stabilizes the blood‑retinal barrier and decreases oxygen demand. This synergy is supported by landmark trials such as the RISE and RIDE studies, which demonstrated superior visual acuity gains when combination therapy was used early in treatment. The DRCR.net Protocol T further highlighted that while aflibercept monotherapy was superior at one year, combination approaches often reduce retreatment frequency.
  • Anti‑VEGF injections plus corticosteroids: Corticosteroids (e.g., dexamethasone implant, fluocinolone acetonide) target inflammatory pathways and can be synergistic with anti‑VEGF agents in persistent DME. The MEAD trial showed that patients receiving both agents required fewer injections and achieved faster resolution of edema compared to anti‑VEGF monotherapy. More recent studies, such as the CLARITY trial for proliferative DR, have also explored anti‑VEGF plus panretinal photocoagulation (PRP) to reduce treatment burden.
  • Combination of laser and intravitreal steroids: Used when anti‑VEGF monotherapy provides an incomplete response or when patients are not candidates for frequent injections, this approach leverages the anti‑inflammatory and anti‑permeability effects of steroids alongside the structural stabilization of laser. Sustained-release steroid implants like dexamethasone (Ozurdex) and fluocinolone acetonide (Iluvien) can provide durable control for months, making them ideal components of a dual regimen.

These approaches aim to address multiple pathogenic pathways simultaneously, potentially improving anatomic and functional outcomes. Clinical trials have demonstrated that dual therapy can achieve faster resolution of edema, reduce the number of injections needed, and maintain visual gains over longer follow‑up periods compared to monotherapy. However, the clinical benefits must be weighed against the additional costs and complexities of combining treatments.

Economic Advantages of Dual Therapy

Long‑Term Cost Savings

While dual therapy increases upfront treatment costs, it may reduce downstream expenses by decreasing the need for more invasive interventions. For example, early and effective control of DME with a combined approach can lower the risk of progression to proliferative diabetic retinopathy, which often requires vitrectomy—a costly surgical procedure with a lengthy recovery. Additionally, fewer clinic visits for monitoring and retreatment may offset the initial expenditure. A systematic review of cost‑effectiveness studies found that many dual‑therapy regimens fall within willingness‑to‑pay thresholds in high‑income countries, particularly when the analysis extends beyond one year.

Real‑world data from large claims databases suggest that patients who receive combination therapy have lower total healthcare costs over two to three years compared to those on anti‑VEGF monotherapy, driven largely by reductions in emergency department visits and hospitalizations for diabetic complications. These savings are especially pronounced when the dual regimen reduces injection frequency, as anti‑VEGF drugs represent a significant proportion of treatment cost. For instance, a 2023 analysis of Medicare claims found that patients on dual therapy with dexamethasone implant and aflibercept had 25% fewer injection visits over two years, translating to an average saving of $4,200 per patient. Another study from the United Kingdom's National Health Service (NHS) estimated that shifting from monthly ranibizumab monotherapy to a combination with laser could save £1,800 per patient annually after the first year, due primarily to reduced injection costs and fewer clinic appointments.

Enhanced Patient Productivity and Quality of Life

Vision preservation directly translates to maintained employment, reduced disability claims, and improved quality of life. Patients with DME who achieve better visual acuity are more likely to remain in the workforce and require less assistance with daily activities. Economic models that incorporate productivity losses consistently show that dual therapy yields higher net monetary benefits than monotherapy when quality‑adjusted life years (QALYs) are factored into the analysis. The intangible value of preserving sight—avoiding depression, social isolation, and loss of independence—further strengthens the case for investing in more effective treatment strategies. A 2021 study using a societal perspective estimated that dual therapy in DME could save over $15,000 per patient in indirect costs over a five‑year horizon. When including caregiver burden, the savings nearly double, as family members often reduce work hours to provide care.

Reduced Healthcare Utilization

Dual therapy can streamline care by lowering the frequency of injections and clinic visits. For instance, combining an anti‑VEGF agent with a sustained‑release corticosteroid implant may extend the interval between treatments from monthly to quarterly, easing the burden on both patients and healthcare systems. This reduction in resource utilization lowers the overall cost burden for payers and frees up capacity for other ophthalmic services. Additionally, by preventing vision loss, dual therapy reduces the long‑term need for low‑vision rehabilitation services, social support programs, and disability payments. A time‑and‑motion study from the United Kingdom estimated that shifting from monthly anti‑VEGF monotherapy to quarterly dual therapy could reduce nurse and physician workload by 40%, representing significant operational savings. In high-volume clinics, this could allow for the treatment of additional patients or a reduction in wait times.

Cost‑Effectiveness Analyses and Real‑World Evidence

Incremental Cost‑Effectiveness Ratios

Health economists evaluate the value of dual therapy using incremental cost‑effectiveness ratios (ICERs), which compare the added cost per additional QALY gained against a benchmark (typically $50,000–$150,000 per QALY in the United States or £20,000–£30,000 in the United Kingdom). Several modeling studies have estimated ICERs for dual therapy in DME that fall within standard thresholds. For example, an analysis of ranibizumab plus laser versus ranibizumab monotherapy showed an ICER below $100,000 per QALY when the analysis considered three‑year outcomes and included indirect costs. Similarly, dexamethasone implant combined with anti‑VEGF therapy yielded favorable ICERs in patients with persistent edema. A recent systematic review of cost‑utility studies in DME concluded that combination approaches are often cost‑effective compared to monotherapy, especially when they reduce the number of injections and improve long‑term visual outcomes. A 2024 Markov model published in Ophthalmology Retina found that aflibercept plus laser had an ICER of $54,000 per QALY for patients with center‑involving DME, well below the commonly accepted U.S. threshold of $100,000.

Budget Impact Models

Beyond cost‑effectiveness, payers need budget impact analyses to understand the financial implications of adopting dual therapy across a population. These models account for the prevalence of DME, current treatment patterns, and expected uptake of new regimens. Results generally indicate that while initial drug and procedural costs rise, savings from reduced hospitalization, fewer surgical interventions, and lower disability payments partially offset the expense. In many scenarios, the net budget impact over five years is manageable, particularly if negotiated pricing or biosimilars are used for anti‑VEGF agents. A 2023 budget impact analysis from a large U.S. insurer estimated that a dual‑therapy protocol could save $1,200 per patient per year after the second year of treatment, with total program costs remaining neutral for the payer after three years. In European healthcare systems with centralized purchasing, similar analyses have predicted net savings as early as year two, driven by reduced ranibizumab volume and fewer laser retreatments.

Challenges to Economic Feasibility

Higher Immediate Costs and Reimbursement Issues

Despite long‑term savings, dual therapy often carries higher upfront costs—combining two drugs or procedures increases the per‑visit expense. In healthcare systems with fixed budgets, payers may be reluctant to approve dual therapy without clear evidence of offsetting savings. Reimbursement policies also vary; some insurers cover combination therapy only after failure of monotherapy, delaying its use to a later, less cost‑effective stage. Furthermore, the cost of administering two treatments in one session may not be fully reimbursed, creating financial disincentives for providers. In the United States, Medicare’s outpatient payment system does not always separately reimburse for both components of a combination procedure, leading to potential revenue loss for practices. Some retina specialists have reported that bundled payment models for hospital outpatient departments sometimes absorb the cost of the second procedure, making combination therapy financially unattractive.

Provider Training and Infrastructure

Delivering dual therapy effectively requires specialized training and equipment. For instance, combining intravitreal injections with laser demands proficiency in both techniques and access to high‑quality laser platforms. In settings with limited resources, the additional training burden may slow adoption, reducing the potential for economic gains. Tele‑retinal screening and referral networks can help, but infrastructure gaps remain a barrier in rural and low‑income areas. A survey of U.S. retina specialists found that only 40% routinely offer combination laser‑injection therapy, citing time constraints and lack of appropriate laser devices as key obstacles. However, emerging technologies such as navigated laser systems and telemedicine‑guided injection programs may lower these barriers.

Patient Adherence and Treatment Burden

Dual therapy may increase the complexity of treatment schedules. Patients who struggle with frequent clinic visits, injection anxiety, or financial copayments may be less likely to adhere to a combined regimen. Poor adherence undermines the clinical benefits and erodes cost‑effectiveness. A 2022 study found that non‑adherence in DME patients was associated with 40% higher total costs over one year, underscoring the importance of patient education and support programs to realize the economic promise of dual therapy. Additionally, patients with comorbidities such as depression or poor diabetes control have higher dropout rates, further limiting the real‑world value of combination approaches. Strategies such as appointment reminders, copayment assistance, and integration with diabetes management programs have been shown to improve adherence by 15–25% in clinical settings.

Policy Implications and Recommendations

To maximize the economic value of dual therapy, policymakers should consider several strategies. Below are key recommendations with actionable steps:

Value‑Based Pricing and Risk Sharing

Value‑based pricing arrangements—where reimbursement is tied to clinical outcomes—can align incentives and reduce financial risk for payers. For example, contracts that link drug pricing to injection frequency reduction or visual outcomes can encourage the use of combination therapy in appropriate patients. The National Institute for Health and Care Excellence (NICE) in the UK has begun incorporating such outcomes-based agreements into its technology appraisals for ranibizumab and aflibercept combinations.

Targeted Use in High‑Risk Populations

Integrating dual therapy into treatment algorithms for high‑risk DME patients—such as those with persistent edema, poor response to monotherapy, or bilateral disease—can target resources to those most likely to benefit. Risk stratification using baseline optical coherence tomography (OCT) biomarkers and systemic factors (e.g., HbA1c, renal function) can improve the cost‑effectiveness of dual approaches. The World Health Organization emphasizes the importance of targeting interventions to high‑need populations in its global action plan for eye health.

Training and Telemedicine Investments

Investments in training, telemedicine, and patient adherence programs can reduce implementation barriers and amplify cost savings. For instance, simulation‑based training for laser procedures and virtual clinics that combine injection visits with telehealth follow‑ups have proven effective in reducing provider time while maintaining safety. The American Academy of Ophthalmology’s IRIS Registry offers benchmarks that can help practices evaluate the efficiency gains from adopting dual therapy.

Bundled Payment and Episode‑Based Reimbursement

Exploring bundled payment models that cover an entire episode of care may encourage providers to adopt more effective, efficient regimens. Under such models, a single payment covers all treatments for a defined period (e.g., one year of DME management), incentivizing the use of strategies that minimize retreatment frequency and hospitalizations. Pilot programs in the Centers for Medicare & Medicaid Services (CMS) have shown promise for ophthalmic conditions.

Comprehensive Economic Evaluations

Health technology assessment agencies should incorporate long‑term indirect costs—such as productivity losses, caregiver burden, and social care—into their evaluations, as these often tilt the balance in favor of more effective treatments. Health policy journals increasingly advocate for such comprehensive economic analyses to inform coverage decisions. For example, a 2024 societal‑perspective cost‑utility analysis of dexamethasone implant combined with aflibercept found that including productivity gains reduced the ICER by nearly 30% compared to a healthcare‑payer perspective alone.

Conclusion

The economic impact of dual therapy in managing diabetic eye complications is shaped by a complex interplay of upfront costs, long‑term savings, patient outcomes, and healthcare system factors. While dual therapy demands greater initial investment, robust evidence indicates that it can reduce overall healthcare expenditures, preserve patient productivity, and improve quality of life. Cost‑effectiveness analyses and real‑world data support its adoption, particularly in patients with high‑risk disease. However, success depends on careful implementation—overcoming reimbursement hurdles, ensuring provider competence, and promoting patient adherence. By weighing these factors thoughtfully, healthcare leaders can harness dual therapy as a cost‑effective tool to combat the growing burden of diabetic eye disease and protect the vision and economic well‑being of millions. As biosimilars reduce drug costs and training programs expand access, the economic case for dual therapy will only strengthen, making it an essential strategy for sustainable eye care delivery.